Processing...
Clinical Trials for Uterine Cancer
Search
Search
There are 148 active trials for advanced/metastatic uterine cancer.
Click on a trial to see more information.
148 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Adults with advanced solid tumors refractory to standard therapy (ECOG 0–1, measurable disease) receive a single intravenous infusion of IDOV-Immune (VM-002), a genetically engineered oncolytic vaccinia virus designed for tumor-selective replication and lysis with immune-stimulating transgenes to enhance antitumor immunity. Key exclusions include prior oncolytic virus therapy, recent vaccinia/smallpox vaccination, active autoimmune disease requiring systemic therapy, significant cardiopulmonary disease, uncontrolled infection, and unstable/untreated CNS metastases.
ClinicalTrials.gov ID: NCT06910657
TrialFetch AI summary: Adults with advanced, refractory solid tumors (ECOG 0–1) receive an allogeneic, off‑the‑shelf iPSC‑derived CAR T product (FT836) targeting stress‑inducible MICA/MICB (engineered to reduce antigen shedding) as monotherapy or combined with trastuzumab (HER2), cetuximab (EGFR), and/or paclitaxel. Multi‑arm cohorts assess safety and preliminary activity to establish RP2D for the combination regimens.
ClinicalTrials.gov ID: NCT07216105
TrialFetch AI summary: Adults with advanced/metastatic NSCLC, SCLC, endometrial cancer, or triple‑negative breast cancer after standard options receive LY4175408, an investigational PTK7‑targeted antibody–drug conjugate delivering an exatecan (topoisomerase I inhibitor) payload, given IV every 21 days. Requires ECOG 0–1 and measurable disease (for later cohorts); excludes prior PTK7 topoisomerase I ADCs, uncontrolled CNS metastases, significant cardiac disease, ILD/pneumonitis, active infection, and prolonged QTc.
ClinicalTrials.gov ID: NCT07046923
TrialFetch AI summary: Adults with refractory locally advanced or metastatic solid tumors limited to NSCLC, TNBC, HNSCC, esophageal (SCC/adenocarcinoma), gastric/GEJ adenocarcinoma, and gynecologic (cervical/endometrial/ovarian) cancers (ECOG 0–1) receive NRM-823, a bispecific T‑cell engager targeting CD3 and a novel tumor antigen, as monotherapy with dose escalation/expansion, with a cohort combining NRM-823 plus an immune checkpoint inhibitor. Primary focus is safety and RP2D determination, with preliminary antitumor activity assessment.
ClinicalTrials.gov ID: NCT07182149
TrialFetch AI summary: Adults with ECOG 0–1 advanced/metastatic CA19-9–expressing solid tumors (including PDAC, cholangiocarcinoma, urothelial, colorectal, gastroesophageal junction, endometrial, and epithelial ovarian cancers) that have progressed after standard therapies; includes a randomized dose-optimization component specifically for second-line or later PDAC with no remaining expected-benefit options. Treatment is IV BNT329, a CA19-9 (sialyl-Lewis A)–targeting antibody–drug conjugate delivering a topoisomerase I inhibitor payload, given q3w or (if opened) q2w, with an optional CA19-9 antibody pre-dosing strategy in one cohort.
ClinicalTrials.gov ID: NCT07186842
TrialFetch AI summary: Adults (ECOG 0–1) with refractory/recurrent locally advanced or metastatic solid tumors—particularly tissue factor–expressing cancers such as HNSCC, NSCLC, esophagogastric, colorectal, pancreatic ductal adenocarcinoma, cervical, endometrial, or urothelial carcinoma—after appropriate prior systemic therapy (prior-line limits vary by study part) are eligible. Treatment is STRO-004, a tissue factor–targeting antibody–drug conjugate delivering an exatecan (topoisomerase I inhibitor) payload, given as monotherapy with dose escalation/expansion or combined with pembrolizumab (PD-1 inhibitor).
ClinicalTrials.gov ID: NCT07227168
TrialFetch AI summary: Enrolling adults (ECOG 0–1) with metastatic/unresectable solid tumors refractory to standard therapy (excluding melanoma, primary brain tumors/GBM, sarcoma, and pancreatic ductal adenocarcinoma; no active untreated brain mets), with expansion cohorts limited to ≤3 prior systemic lines and focused on PD-(L)1–naïve MSS colorectal cancer without liver metastases and PD-1 relapsed/refractory MSS endometrial cancer, RCC, or NSCLC. Patients receive IV ADU-1805 (anti-SIRPα mAb blocking the SIRPα–CD47 “don’t eat me” checkpoint to enhance myeloid/macrophage activity) every 3 weeks alone or with fixed-dose pembrolizumab every 3 weeks.
ClinicalTrials.gov ID: NCT05856981
TrialFetch AI summary: Enrolls adults with metastatic or locally advanced unresectable solid tumors (ECOG ≤2; measurable/evaluable by RECIST) with biologic rationale for RBM39 degradation; adolescents ≥16 may enroll for Ewing sarcoma or other supported malignancies, and stable treated brain metastases are allowed. Patients receive oral ST-01156, a small-molecule molecular glue RBM39 degrader (RNA-binding/splicing factor), dosed once daily on a 5-days-on/2-days-off schedule in 28-day cycles with dose escalation to define MTD/RP2D and assess early antitumor activity.
ClinicalTrials.gov ID: NCT07197554
TrialFetch AI summary: Eligible patients are adults with advanced NSCLC, head and neck squamous cell carcinoma, cervical cancer, or uterine carcinoma, whose tumors express the NEO-201 antigen and who have progressed after standard therapies. Treatment consists of NEO-201 (a monoclonal antibody targeting tumor-associated O-glycans and CEACAM5/1 pathway) in combination with pembrolizumab.
ClinicalTrials.gov ID: NCT03476681
TrialFetch AI summary: This trial enrolls adults with advanced or metastatic solid tumors or diffuse large B-cell lymphoma who have exhausted standard therapies, evaluating the investigational oral CBL-B inhibitor NX-1607 (which enhances antitumor immunity by blocking a negative regulator of immune cell activation) as monotherapy or in combination with paclitaxel. Eligible tumor types include ovarian, gastric, head and neck, melanoma, NSCLC, prostate, mesothelioma, triple-negative breast, urothelial, cervical, microsatellite-stable colorectal cancer, and DLBCL/Richter transformation.
ClinicalTrials.gov ID: NCT05107674